The outlook of companies tied to the drug's legacy presents a challenging investment scenario . While the initial success generated substantial returns , generic copies have significantly eroded market share . Investing in connected pharmaceutical firms now requires a discerning assessment of patent safeguards, evolving healthcare changes, and the